(Ask an Expert) Efficient development of gene therapy and vaccines through comprehensive viral vector characterization

Log in to watch this webinar

Not registered yet? Create an account

Ever-more structurally complex bio-molecules and biological entities are coming into focus within the pharma development space, with fit-for-purpose analytics becoming more important to their success. Reducing development time and optimising formulation through applying orthogonal analytical technologies is key to bringing them to market in an efficient, risk-free manner.

In addition to synthetic nanoparticles, viral capsids are also increasingly used as vectors in gene therapy and vaccines (such as those used in the Covid-19 pandemic). These include the lentivirus, rAAV and Adenovirus vectors.

In order to develop efficient virally-vectored therapies produced through controlled and economical manufacturing processes, multiple challenges need to be addressed. These range from capsid design through to identification of optimal process and formulation conditions to comprehensive quality control of Drug Substance and Drug Product. 

Addressing these challenges require extensive characterization including measurements of capsid size & count, % full, aggregate formation, stability, genome release and capsid charge.

In this webinar, Michael Caves will demonstrate how Dynamic Light Scattering, Differential Scanning Calorimetry, nanoparticle tracking analysis (NTA) and multi-detection SEC (SEC-MALS) can be used orthogonally to optimise the efficiency of gene therapy development and ensure such products are bought to market as quickly and affordably as possible. This webinar is part of Malvern Panalytical's "Ask an Expert" series on gene therapy and other viral vectors. Scroll down for more.

Join our free MasterClass series on gene therapy and viral vectors analysis

- Webinar 1: Efficient development of gene therapy and vaccines through comprehensive viral vector characterization

- Webinar 2: Quantifying rAAV and other viral vector quality attributes with Multi-angle DLS and nanoparticle tracking analysis. More info

- Webinar 3: Optimising loading time and stability of virally vectored therapies and vaccines using SEC and DSC. More info


Dr Michael Caves, Malvern Panalytical's Pharma segment manager

Dr Michael Caves has spent 20 years working in various academic and commercial life science settings. He has published scientific papers on biotherapeutic characterization and formulation, and has applied this knowledge during various roles within the pharmaceutical and diagnostics industries. Having helped build the formulation development service at SGS Life Sciences, Michael joined Malvern Panalytical in 2013 in order to support customers around the world. Michael is currently based in Chennai, India, from where he focuses on helping customers across Asia’s pharmaceutical industry.

Questions les plus fréquentes

Who should attend?

  • Scientists working on development of viral vector gene therapies and viral vaccines.
  • Anyone who wants to expand their analytical characterization knowledge

How long is this webinar?

  • 30 minutes is the intended speaker time with additional time for addressing queries.